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Regulatory T cells (Treg) play some important roles in allergic rhinitis. The most speciﬁc marker for Treg is FOXP3, a recently
identiﬁed transcription factor that is essential for Treg development. In order to clarify the levels of Treg in allergic nasal
mucosa, we studied the relationship between FOXP3-expressing cells and Th1-Th2 balance in nasal mucosa by means of
immunohistochemistry. Human turbinates were obtained after turbinectomy from 26 patients (14 patients with perennial allergic
rhinitis and 12 patients with nonallergic rhinitis). To identify the cells expressing the FOXP3 protein, double immunostaining
was performed by using anti-FOXP3 antibody and anti-CD3 antibody. There was no signiﬁcant diﬀerence in the percentage
of FOXP3+CD3+ cells among CD3+ cells in the nasal mucosa of two groups. The proportion of FOXP3+CD3+ cells tend to
be correlated positively with GATA3+CD3+ cells/T-bet+CD3+ cells ratio (R = 0.56, P = 0.04). A positive correlation with
GATA3+CD3+/T-bet+CD3+ratioandFOXP3+CD3+/CD3+ratiosuggeststheroleoflocalregulatoryTcellsasaminimalcontrol
of the chronic allergen exposure in nasal mucosa.
1.Introduction
The allergic response is a complex process characterized
by an aberrant immune response to inhaled environmental
allergens. CD4+ lymphocytes with a Th2 phenotype may
play some important roles in the development of allergic
rhinitis, and the suppression of Th2 lymphocytes could
have the potential to be new therapeutic targets for the
treatment of allergic rhinitis. The CD4+ CD25+ regulatory
T (Treg) cells have been shown to suppress both Th1 and
Th2 responses in vitro [1–3]. The most speciﬁc marker for
Treg cells is FOXP3 as identiﬁed transcription factor that is
essential for the development of Treg cells.
Impaired skin inﬁltration of CD4+CD25+FOXP3+ T
cells was observed in acute atopic dermatitis lesions [4],
suggesting a dysregulated control of inﬂammation by Treg
cells. With regard to the local FOXP3-expressing cells in
allergic nasal mucosa, conﬂicting results have been reported
regardingdiﬀerenceinthelevelsofFOXP3-expressingcellsin
betweenallergicandnonallergicnasalmucosa.Inthepresent
study, we evaluated the number of FOXP3+ cells and the fre-
quencies of FOXP3+ T lymphocytes in perennial allergic
and nonallergic nasal mucosa by dual-immunoﬂuorescence
methods.
2.MaterialandMethods
2.1. Subjects. Human inferior turbinates were obtained after
turbinectomyfrom26patientswithnasalobstructionrefrac-
tory to medical therapy. Informed consent was obtained
from all patients and this study was approved by the
ethics committee of Sapporo Medical University. All were
nonsmokers, and 14 patients had perennial allergy against
mites as deﬁned by questionnaire and CAP test (Pharmacia,
Uppsala, Sweden). ENT doctors of our hospital reviewed the
questionnairesanddeterminedtheclinicaldiagnosis.Subject
without allergies (nonallergic rhinitis: control group) had
to satisfy the following criteria: (1) no history of allergic
diseases, (2) no detectable, speciﬁc IgE antibodies against
4 major inhalant allergens (RAST score < class 1), and (3)
totalserumIgElevelsbelowthegeneralpopulationmean.All
medications, including glucocoriticoids, were prohibited for2 International Journal of Otolaryngology
Table 1: Demographic characteristics of perennial allergic and nonallergic patients.
Perennial allergic rhinitis Nonallergic rhinitis
n = 14 n = 12
Sex (male/female) 6/8 6/6
Age 38 (19–65) 36 (19–58)
Speciﬁc IgE to house dust mite (d1) (kU/L) 3.3 (1.0–26) <0.35
Speciﬁc IgE to birch (t3) (kU/L) 0.15 (0–2.4) <0.35
Speciﬁc IgE to orchardgrass (g3) (kU/L) 0.23 (0–1.1) <0.35
Speciﬁc IgE to mugwort (w6) (kU/L) 0.20 (0–2.1) <0.35
Total IgE (kU/L) 235 (10–523) 101 (10–210)
Blood eosinophils (cells/μL) 378 (70–740) 110 (45–240)
Current nasal symptoms (number of patients)
Nasal obstruction 14 (all patients) 12 (all patients)
Sneezing 8 1
Rhinorrhea 6 3
Data expressed as median values and range (in brackets).
at least 3 weeks prior to the study. Demographic and clinical
characteristics of the patients are summarized in Table 1.
The nasal mucosal specimens were ﬁxed in 10% formalin for
immunohistochemistry.
2.2. Immunohistochemistry
2.2.1. Antibodies. For immunohistochemistry of FOXP3,
rabbit anti-human FOXP3 polyclonal antibody (catalog #
623802, BioLegend, CO, USA) was used at 1:40 dilutions.
For immunohistochemistry of T-bet, rabbit anti-human
T-bet polyclonal antibody (catalog#sc-21003, Santa Cruz
Biotechnology Inc. CA, USA) was used at 1:100 dilutions.
For immunohistochemistry of GATA3, goat anti-human
GATA-3 polyclonal antibody (catalog#sc-22206, Santa Cruz
Biotechnology Inc.) was used at 1:40 dilutions. To identify
the T lymphocytes, anti-CD3 monoclonal antibody (F7.2.38
clone, Dako Corporation, Carpinteria, CA, USA) was used.
2.2.2. Immunohistochemistry. For double staining of CD3
and FOXP3 or T-bet, deparaﬃnized sections were stained by
immunoﬂuorescence technique. After microwave treatment
(10 minutes at 500 Watt in citrate buﬀer), the deparaﬃnized
sections were incubated in blocking solution (10% normal
goat serum in PBS) for 30 minutes before incubation in
primary antibody. Then, the sections were incubated with
anti-CD3 monoclonal antibody and anti-FOXP3 polyclonal
antibody or anti- T-bet polyclonal antibody for overnight at
4◦C, washed in PBS, and were incubated for 30 minutes with
Alexa Fluor 594-labelled goat anti-mouse IgG (diluted 1:50;
Molecular Probes, OR, USA) and Alexa Fluor 488-labelled
goat anti-rabbit IgG (diluted 1:50; Molecular Probes).
For double staining of CD3 and GATA-3, deparaﬃnized
sections were stained by the similar immunoﬂuorescence
technique with minor modiﬁcation. After microwave treat-
ment (10 minutes at 500 Watt in citrate buﬀer), the deparaf-
ﬁnized sections were incubated in blocking solution (10%
normal rabbit serum in PBS) for 30 minutes before incuba-
tion in primary antibody. Then, the sections were incubated
with anti-CD3 monoclonal antibody and anti-GATA3 poly-
clonalantibodyforovernightat4◦C.AfterwashingwithPBS,
the sections were incubated with Alexa Flour 594-labelled
rabbit anti-mouse IgG (diluted 150; Molecular Probes) and
Alexa Flour 488-labelled rabbit anti-goat IgG (diluted 1:50;
Molecular Probes). After washing with PBS, the sections
were mounted with Vectashield mounting medium with
4 ,6 diamidino-2-phenylindole (DAPI) (Vector Laboratories
Inc, Burlingame, CA, USA) and examined under Olympus
BX51 microscope, DP70 CCD camera (Olympus Optical
Co., Tokyo, Japan). All images were processed with DP
Controller and DP Manager Software (Olympus Optical
Co) for image analysis. Negative controls were obtained by
replacing primary antibodies by mouse IgG1 and rabbit
immunoglobulin fraction (Dako).
2.2.3. Quantitation. For double immunoﬂuorescence stain-
ing, the slides were counted using a microscope equipped
with an eyepiece graticule. A total of 6 ﬁelds (1mm2 each)
fromeachslidewerecountedbyplacingtheupperedgeofthe
grid at the epithelium. The number of FOXP3+CD3+ cells,
T-bet+CD3+ cells, or GATA-3+CD3+ cells in CD3+ cells in
allergic and nonallergic nasal mucosa was evaluated by 2
blinded investigators. Results are expressed as the number
of FOXP3-positive cells per square millimeter (mm2)a n d
the percentage of FOXP3+CD3+cells, T-bet+CD3+cells, or
GATA-3+CD3+ cells in CD3+ cells.
2.2.4.StatisticalMethods. Valuesareexpressedasmean ±SD.
Diﬀerences between groups are compared using the Mann
Whitney U-test. A P<0.05 was considered signiﬁcant.
Linearregressionanalysiswasusedtodeterminetherelation-
ship between the percentage of FOXP3+ cells in CD3+ cells
and the ratio of GATA3+ CD3+ cells/T-bet+ CD3+ cells in
allergic nasal mucosa.International Journal of Otolaryngology 3
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Figure 1: Identiﬁcation of the cells expressing FOXP3 among CD3 positive cells in human allergic nasal mucosa by means of
immunoﬂuorescence technique as follows: (a) the FOXP3 protein (green), (b) CD3 (red), (c) nuclear stain with 4 ,6 diamidino-2-
phenylindole (DAPI: blue), and (d) The overlay images. The immunoreactivity for FOXP3 was signiﬁcantly detected in nucleus of some
CD3 positive cells. Scale bar = 100μm.
3. Results
As shown in Figure 1, immunoreactivity for FOXP3 was
signiﬁcantly detected in nucleus of some CD3+ cells. Simi-
larly, immunoreactivity for T-bet (Figure 2(a))a n dG A T A 3
(Figure 2(b)) was signiﬁcantly detected in some of CD3+
cellsinbothallergicandnonallergicnasalmucosa.Speciﬁcity
of the staining was also conﬁrmed by the absence of labeling
with normal mouse IgG1 and rabbit immunoglobulin (data
not shown).
As shown in Figure 3, no signiﬁcant diﬀerence between
the group was found in terms of the number of
FOXP3+CD3+ cells (allergic rhinitis: 12.5 ± 4.4, nonallergic
rhinitis 10.6 ± 4.0, P = 0.23).
Next, we compared percentage of T-bet+ CD3+ cells/
CD3+ cells, GATA3+CD3+ cells/CD3+ cells, and FOXP3+




T cells are signiﬁcantly higher in allergic nasal mucosa than
those in nonallergic nasal mucosa (allergic rhinitis: 3.9 ±
1.8%, nonallergic rhinitis 1.1 ± 0.6%, P = 0.003).
Finally, we compared FOXP3+CD3+ cells to Th2/Th1
ratio in allergic nasal mucosa. As shown in Figure 5, the
proportion of FOXP3+CD3+ cells in allergic nasal mucosa
tend to be correlated positively with GATA3+/T-bet+ cells
ratio (R = 0.56, P = 0.04). The slope of the regression line
for percentage of FOXP3-positive T cells against Th2/Th1
ratio was 0.77.
4. Discussion
In this study, the average number of FOXP3+ cells in allergic
mucosa is higher than that in nonallergic mucosa. How-
ever, the diﬀerence between the groups is not statistically
signiﬁcant due to high standard deviation in both groups
(allergic rhinitis: 12.5 ± 4.4, nonallergic rhinitis 10.6 ± 4.0,
P = 0.23). With respect to the number of FOXP3+ T
cells in nasal mucosa, conﬂicting results have been reported
regarding the diﬀerence between in allergic and in nonal-
lergic nasal mucosa. Malmh¨ all et al. demonstrated that the
number of FOXP3+ cells in the nasal mucosa of patients
with allergic rhinitis was signiﬁcantly increased compared
with healthy subjects, and that seasonal increases in FOXP3+
cells in nasal biopsy specimens compared with baseline4 International Journal of Otolaryngology
(a)
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Figure 2: Identiﬁcation of the cells expressing T-bet and GATA-3
proteininhumannasalmucosa.(a)ThedualstainingforCD3(red)
and T-bet (green) in allergic nasal mucosa. The arrows indicate the
cell expressing T-bet in nucleus of CD3 positive cells. (b) The dual
stainingforCD3(red)andGATA-3(green)inallergicnasalmucosa.
The arrows indicate the cell expressing GATA-3 in nucleus of CD3
positive cells. Scale bar = 100μm.
values were observed in both placebo- and immunotherapy-
treated patients with grass pollen allergy [3]. In addition,
nasal challenge with pollen extract increased the number
of FOXP3+ T cells at the inﬂammatory site in pollen-
allergic patients [5]. These reports suggest that local allergen
exposure induces the increases of local FOXP3+ T cells [6].
On the contrary, another study has demonstrated that
nasal secretions of patients with allergic rhinitis had sig-
niﬁcantly lower FOXP3 mRNA compared to nonallergic
controls [2]. From these observations, further studies will
be necessary to determine whether the upregulation or
downregulation of local T-regulatory cells may exist in
patients with allergic rhinitis.
In the present study, we focused on the local Th1/Th2
balance and regulatory T cells, and our study demonstrates a
positive correlation between FOXP3+CD3+ cells/CD3+ cells
andGATA3+CD3+cells/T-bet+CD3+cellsratio.Ithasbeen
well known that IL-4 is one of the most important cytokine
on the local Th1/Th2 balance, because IL-4-induced GATA3





























Figure 3: The number of FOXP3+CD3+ cells in allergic and non-
allergic nasal mucosa by means of double immunoﬂuorescence
staining for FOXP3 protein and CD3. There are no signiﬁcantly








Allergy (n = 14)
Non-allergy (n = 12)
P = 0.47






















Figure 4: The percentage of T-bet-, GATA3-, or FOXP3-positive T
lymphocytes in allergic (n = 14) and nonallergic (n = 12) nasal
mucosa. Sections were stained by double immunohistochemistry
(IHC) using anti-CD3 antibody and antibody against each tran-
scription factor protein. The percentage of double-positive cells to
IHC-positive cells was calculated. Data are the mean ± SD.
been shown to negatively regulate the development of na¨ ıve
T cells into Th1 or the IL-17-producing T cells (Th17)[7].
It is well known that FOXP3+ T cells accumulate in a
variety of human inﬂammatory disorders. One possibility,
of course, is that the accumulation of FOXP3+ cells, at






































) y = 0.77x +2.84
R = 0.56
P = 0.04
Figure 5: The correlation between the percentage of FOXP3-
positive T lymphocytes and Th1/Th2 ratio in allergic nasal mucosa
(n = 14). Linear regression analysis was used to determine the
relationshipbetween thepercentage ofFOXP3-positivecell inCD3-
positivecells and theratio ofGATA-3+CD3+cells/T-bet+ CD3cells
in allergic nasal mucosa.
TGF-β and other cytokines. With respect to the eﬀect of IL-
4 on the induction of FOXP3, conﬂicting results have been
reported in mice in vitro. Skapenko et al. demonstrated that
IL-4 induced the generation of FOXP3+ regulatory T cells
[8]. This observation may support our present data. On the
other hand, Mantel et al. reported that FOXP3 expression
was negatively regulated by IL-4 [9]. Whether or not Th2
cytokines such as IL-4 directly aﬀect the accumulation of the
regulatory T cells is still unclear and needs to be clariﬁed.
There have been several reports regarding the circulating
regulatory T cells by mean of ﬂow cytometory. It was found
in peripheral blood of pollen-sensitized children that Treg
cells increase during the pollen season [10]. Circulating Der
p1-speciﬁc CD4+CD25hiFOXP3+ Treg cells obtained from
atopic patient inhibited antigen-induced proliferation of T
cells [11]. These results suggest that the Treg cells keep
the inﬂammation at low levels. Another study found that
circulating FOXP3+/CD4+ ratio was signiﬁcantly low in
patients with asthma and atopic dermatitis [12]. Whether
these Treg cells directly contribute to allergic inﬂammation
or not remains an important research question.
Allergen-speciﬁc immunotherapy, which consists of
repeated subcutaneous or sublingual administration of aller-
gen, has been widely used and proved eﬀective for the
management of allergic rhinitis. The mechanism of the
therapeutic eﬀect of allergen-speciﬁc immunotherapy is not
completely understood but might involve the activation and
expansion of Treg cells. It is well established that FOXP3
acts as master transcription factor for naturally occurring
regulatory T cells (nTreg) development and function [13].
Several mechanisms involving Treg in tolerance induc-
tion after allergen-speciﬁc immunotherapy have been doc-
umented. Such mechanisms include increased capacity of
Treg to suppress Th1 and Th2 cells [14], induction of IL-
10 and TGF-beta [14], decreased allergen-stimulated T cell
proliferation [15], or suppression of eﬀector cells [16]. The
induction of a tolerant state in peripheral T cells represents
anessentialstepinallergen-speciﬁcimmunotherapy.Periph-
eral T cell tolerance is characterized mainly by generation
of allergen-speciﬁc Treg cells and suppressed proliferative
and cytokine responses against the major allergen. It is
initiated by the autocrine action of IL-10 and TGF-β,
which are increasingly produced by the antigen-speciﬁc TR1
cells [17]. It was shown that grass pollen immunotherapy
increased the expression of mucosal and peripheral T-cell
IL-10 [18]a n dT G F - β [19]. It has been shown that the
increased number of FOXP3+CD25+ Treg in nasal mucosa
after grass pollen immunotherapy correlated with clinical
eﬃcacy and suppression of seasonal allergic inﬂammation,
thus supporting the role of Treg in the induction of allergen-
speciﬁc tolerance in human subjects [6]. From these reports,
we suppose that the exposure of allergen locally or generally
may increase the number of Treg cells in nasal mucosa
of perennial allergic rhinitis patients. So, further studies
on nasal mucosa from the perennial rhinitis patients who
received immunotherapy will be necessary to clarify the roles
of immunotherapy on the local Treg cells and Th1-Th2
balance in perennial allergic rhinitis.
In conclusion, we have demonstrated a positive correla-
tion with GATA3+CD3+ cells/T-bet+CD3+ cells ratio and
FOXP3+CD3+ cells/CD3+ cells ratio, suggesting that Treg
cells are operative on Th1-Th2 balance in perennial allergic
nasalmucosa.Ourpresentﬁndingsshouldbeofconsiderable
interest for understanding the role of regulatory T cells on
upper airway diseases such as allergic rhinitis.
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